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ABSTRACT
To investigate the effect of granulocyte colony-stimulating factor (G-CSF) donor-marrow priming on hematopoietic
recovery and clinical outcome after allogeneic hematopoietic stem cell transplantation, we compared HLA-matched
related marrow transplantation with and without G-CSF donor priming in a prospective randomized study for a
homogeneous group of chronic myelogenous leukemia (CML) patients. Fifty patients (aged 12-41 years) with CML
were enrolled in the study. Thirty-two patients (study group) received the marrow grafts primed with G-CSF at 3 to
4 µg/kg per day for 7 days prior to the marrow harvest, and 18 patients (control group) received the marrow grafts
without G-CSF priming. All patients received the same graft-versus-host disease (GVHD) prophylaxis (cyclosporine
A and methotrexate) and postgraft G-CSF treatment, 3 to 4 µg/kg daily until the absolute neutrophil counts (ANCs)
were >109/L. The primary end points were engraftment and incidence of acute GVHD. The secondary end points
were the incidence of chronic GVHD, relapse, and overall disease-free survival. The study and control groups were
comparable for age, sex, donor selections, conditioning regimens, and disease status. The median times to both
neutrophil and platelet engraftment (ANC > 0.5 × 109/L; platelets > 20 × 109/L) were significantly faster in the study
group than in the control group, at 15 versus 21 days (P < .001) and 17.5 versus 24 days (P < .001), respectively.
G-CSF donor priming yielded significantly higher numbers of total nuclear cells in the marrow grafts compared to
the numbers in the control grafts (7.2 versus 2.9 × 108/kg, P < .001). Similar results were seen for CD34+ (6.1 versus
2.7 × 106/kg, P < .001) and colony-forming unit–granulocyte/macrophage (CFU-GM) cells (68 versus 16 × 104/kg,
P < .001). The incidence of grades II to IV acute GVHD was surprisingly low in the study group: only 2 (6.3%) of 32
transplantation patients in the study group developed grade II acute GVHD, limited to the skin, whereas 5 (27.8%)
of 18 patients in the control group developed grades II to IV acute GVHD (P = .032). G-CSF priming did not
change the total numbers of CD3+ cells in the marrow grafts but lowered CD4+ cells and increased CD8+ cells,
resulting in a significant reduction of CD4:CD8 ratio (P = .018). Six patients in the study group developed chronic
GVHD either during or after cyclosporine taper. There were no significant differences in chronic GVHD (24% ver-
sus 33.3%), relapse rates (12.5% versus 11.1%), and overall survival rates (78.1% versus 66.7%, P = .32) between the
study and control groups during a median follow-up period of 24 months (range, 6-50 months). There was, how-
ever, a trend in favor of improved chronic GVHD and disease-free survival in the study group. We conclude that
G-CSF donor-marrow priming accelerates both neutrophil and platelet engraftment and is associated with a very
low incidence of grades II to IV acute GVHD in CML patients after HLA-matched sibling marrow transplantation.
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INTRODUCTION
Granulocyte colony-stimulating factor (G-CSF) can pro-
mote cell cycling of multipotential hematopoietic pro-
genitors and increase hematopoietic progenitor cell yields in
both marrow and peripheral blood [1,2]. Many studies have
shown that G-CSF–mobilized peripheral blood progenitor
cells (PBPCs) accelerate engraftment and shorten the neu-
tropenic period compared to non–G-CSF–primed steady-
state marrow graft [3-6]. G-CSF–mobilized peripheral blood
stem cells (PBSCs) spared the donors from the marrow har-
vest procedure. However, the numbers of T-cells in PBSC
collection are 10 to 15 times higher than the numbers in the
steady-state marrow graft [7,8]. It is known that donor T-cells
in the graft are closely associated with the incidence of graft-
versus-host disease (GVHD), especially the mature T-cells
collected from the peripheral blood mononuclear fraction
[9]. The potential advantage of G-CSF–mobilized PBPCs
still needs to be balanced against the currently undeﬁned risk
of GVHD that may be associated with the infusion of much
higher donor T-lymphocyte numbers in unmanipulated allo-
geneic PBSCs than in marrow graft [10,11].
Several pilot studies compared the effects of G-CSF–
mobilized PBSCs versus G-CSF–primed marrow on hema-
tological recovery and GVHD after allogeneic transplantation
[12,13]. The neutrophil recoveries were equivalent in both
groups, and the results were very consistent among those
studies, although the platelet recoveries were somewhat
inconsistent. Patients receiving G-CSF–primed marrow
appeared to have a lower incidence of chronic GVHD than
did those receiving G-CSF–mobilized PBSCs. It is unclear
how G-CSF priming affects relapse rates and overall survival
rates because of these studies’ mixed patient populations,
small patient numbers, and short follow-up periods. This
prospective randomized study compared the outcomes of
using G-CSF–primed marrow versus steady-state marrow as
the stem cell source for HLA-matched sibling transplanta-
tion in chronic myelogenous leukemia (CML) patients, with
a medium follow-up of 24 months (range, 6-50 months).
PATIENTS AND METHODS
Patients
Patients aged 12 to 50 years with a conﬁrmed diagnosis
of CML and an HLA-identical sibling donor were eligible
to participate in the study. The CML diagnosis and classiﬁ-
cation were confirmed by morphologic and cytogenetic
analyses of the bone marrow immediately before transplan-
tation. Patients were classified as having chronic phase or
accelerated phase according to Hammersmith criteria [14].
The donor and recipient matching was based on the HLA-
genotypical typing (A, B, DR) and negative mixed lympho-
cyte reactions between the donor and recipient. All patients
were enrolled from the Air Force General Hospital (AFGH)
after the discussion of potential risks and benefits of the
study. The study protocol was approved by the Institutional
Review Board (IRB) at the AFGH. The patients were
prospectively allocated into the donor G-CSF–priming
group or the nonpriming group using monthly cycle ran-
domization, ie, ﬁrst month to non–G-CSF–priming group
(control group), second month to G-CSF–priming group
(study group). The cycle repeated every 2 months. The pri-
mary end points were engraftment and incidence of acute
GVHD. The secondary end points were relapse rate, inci-
dence of chronic GVHD, and overall survival rate. Within
6 months after the ﬁrst 15 patients were enrolled, a trend
strongly suggested fast engraftment without the develop-
ment of acute GVHD in the donor G-CSF–priming group.
After discussions with the IRB and statistician, we decided,
because of the beneﬁt to patients, to increase the number of
patients in the study group. The patient assignment was then
changed to ﬁrst month to the non–G-CSF–priming control
group and the second and third month to the G-CSF–
priming study group. The cycle was repeated every 3 months.
Patient accrual was initiated in January 1997 and terminated
in September 2000 after we were notiﬁed that both primary
end points achieved signiﬁcant difference between the study
and control group.
Donor Priming Regimen and Bone Marrow
Harvesting
Informed consent was obtained from each donor using
the forms approved by the IRB at the AFGH. Donors were
primed with G-CSF (lenograstim) (Chugai Pharmaceuti-
cal, Tokyo, Japan) at 3 to 4 µg/kg per day by a single daily
subcutaneous injection for 7 consecutive days as previously
described [15-17]. On the eighth day the bone marrow
cells were harvested from the posterior iliac crests while
the patients were under epidural anesthesia, with approxi-
mately 10 mL of bone marrow collected per each aspira-
tion. The target volume for each donor marrow collection
was 18 to 20 mL/kg recipient body wt. Total nucleated cell
(TNC) counts were obtained using an automated counter
instrument. The numbers of CD34+ and CD3+, CD4+, and
CD8+ T-cells were assessed by immunophenotyping and
flow cytometric analysis. The fresh and unmanipulated
marrow was infused on the same day after the marrow har-
vest (day 0). In ABO major blood group incompatibility,
the red cells in the marrow were removed by sediment
manipulation.
Conditioning Regimen
For patients with CML in chronic phase, the condition-
ing regimens were either cyclophosphamide (Cy) 120 mg/kg
over 2 days and total body irradiation (TBI) with 1000 cGy
by 2 fractions at a dose rate of 5 to 6 cGy/min (Cy + TBI); or
busulfan (Bu) 16 mg/kg administered orally in 16 doses over
4 days plus Cy 120 mg/kg over 2 days (BuCy). In February
1998, our original study of overall leukemia patients (CML,
acute myelogenous leukemia, acute lymphoblastic leukemia)
with standard risk showed that BuCy conditioning regimens
were superior to Cy + TBI conditioning, with lower rates of
transplantation-related complications and signiﬁcantly lower
cost [17]. After February 1998, the conditioning regimen for
all standard-risk leukemia patients was changed to BuCy. For
all high-risk patients with CML accelerated phase or disease
duration >3 years, the regimen consisted of Bu (8 mg/kg in
8 doses over 2 days), Cy (120 mg/kg over 2 days), and TBI
1000 cGy in 2 fractions [17].
Supportive Care
All patients were hospitalized in rooms with high-efﬁciency
particulate air filters and received standard antibiotic
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prophylactic therapy consisting of oral trimethoprim-
sulfamethoxazol (TMP-SMZ), fluconazole, and acyclovir.
Intravenous immunoglobulins were given at a dosage of
500 mg/kg weekly starting on day 1. G-CSF (lenograstim),
3 to 4 µg/kg per day, was given to all recipients subcuta-
neously from the second day of transplantation until the
neutrophil counts reached 0.5 × 109/L for 3 consecutive
days. Patients received transfusions if hemoglobin or platelet
levels were below 8.0 g/dL or 20 × 109/L, respectively. All
blood products were irradiated.
GVHD Prophylaxis
All patients received cyclosporine A (CsA) and methotrex-
ate (MTX) for GVHD prophylaxis. The dosage of MTX
was 7.5 mg/M2 intravenously on days 1, 3, 6, and 11 post-
transplantation. The dosage of CsA was 2.5 mg/kg per day
intravenously on day –1 until bowel function was normal
and then 5 mg/kg per day orally in 3 divided doses. From
day 50, the dosage was reduced by 5% every week and
stopped on day 180 if there was no chronic GVHD. If
chronic GVHD developed, CsA was continued for a longer
time. Whole-blood CsA trough levels were measured
weekly using fluorescence polarization immunoassay. The
CsA dose was reduced if the trough level of CsA was more
than 300 ng/mL or the serum creatinine level exceeded
2 mg/dl. The diagnosis and grading of GVHD was estab-
lished according to previous definable criteria [18]. Acute
GVHD of grade II or higher was treated with methylpred-
nisone 1 to 2 mg/kg per day.
Evaluation of Engraftment
Engraftment was defined as absolute neutrophil count
(ANC) > 0.5 × 109/L after neutrophil nadir. Bone marrow
aspiration, biopsy, and cytogenetic studies were done at
1 month posttransplantation to assess engraftment. Further
bone marrow evaluations were done if clinically indicated.
Progenitor Cell and T-Cell Analyses in the Marrow
Grafts
Cell surface markers were determined by the dual or
3-color staining method using monoclonal antibodies
directly against CD34+, CD3+, CD4+, and CD8+ (Coulter,
Fullerton, CA). The marrow cells were incubated with the
monoclonal antibodies for 15 minutes at room temperature.
The cells were then washed and analyzed by ﬂow cytometer
(EPICS XL, Coulter). The numbers of CD34+ and subsets
of T-cells were calculated by the numbers of total nuclear
cells per microliter, multiplying the percentage of their cor-
responding immunophenotype. CFU-GM was determined
by semisolid agar culture [19].
Statistical Analysis
Patients, disease stages, and transplantation-related
characteristics were compared between the study and con-
trol groups using the chi-square test. A comparison between
classiﬁed variables was performed by the Fisher exact test.
The Student t test was used to compare the means of con-
tinuous variables between the 2 groups. The cumulative
probabilities of GVHD, relapse rate, and disease-free sur-
vival were calculated using the Kaplan-Meier and log-rank
tests. The date of the ﬁnal analysis was March 15, 2001.
RESULTS
Patient Characteristics
Fifty patients with Philadelphia chromosome–positive
CML undergoing allogeneic transplantations from HLA-
identical siblings were enrolled in this study. Thirty-two
patients, of which 27 were in chronic phases and 5 in acceler-
ated phases, were allocated into the study group with donor
G-CSF priming, and 18 patients, of which 15 were in
chronic phases and 3 in accelerated phases, were allocated
into the control group without donor G-CSF priming. All
patients underwent transplantations during the same time
period. Both groups of patients were comparable in the most
important parameters such as patient age, sex, disease status,
donor selections, and conditioning regimens (Table 1).
Marrow Graft Characteristics
Table 2 summarizes the contents of marrow grafts in the
study and control groups. The median volumes harvested
were 1.10 L (range, 0.60-1.50 L) in the study group and
1.20 L (range, 0.75-1.60 L) in the control group, with the
goal being 18 to 20 mL/kg of recipient body wt. The
median numbers of TNCs, CD34+ cells, and CFU-GM cells
were significantly higher in the study group (P < .001)
Table 1. Patient and Transplantation Characteristics
Study Group Control Group P
No. of patients 32 18
Age, median (range), y 32.5 (12-42) 29 (16-41) .9
Sex, F/M 10/22 6/12 .91
Disease status at BMT .91
CML, chronic phase 27 15
CML, accelerated phase 5 3
Interval from diagnosis to BMT .95
<1 year 8 6
2-3 years 17 8
>3 years 7 4
Conditioning regimens .99
Cy + TBI 7 4
Bu + Cy + TBI 9 5
Bu + Cy 16 9
Donor age, median (range), y 30 (15-42) 27 (17-48) .9
Donor sex, F/M 14/18 7/11 .92
Donor/recipient sex match .9
M/M 10 6
F/M 12 6
M/F 8 5
F/F 2 1
Table 2. Graft Characteristics*
Study Group Control Group P
TNC, ×108/kg 7.2 (3.5-11.5) 2.9 (1.9-4.6) .001
CD34+, ×106/kg 6.1(3.5-11.2) 2.7 (1.4-4.2) .001
CFU-GM, ×104/kg 68 (32-96) 16 (8-27) .001
CD3+, ×106/kg 35.7 (27-43.0) 34.5(28-42.2) .9
CD4+, ×106/kg 16.0 (10.2-24.4) 20.2 (15.8-29.3) .02
CD8+, ×106/kg 16.2 (9.5-25) 12.9 (8.8-20.9) .02
*Values are median (range).
S.-Q. Ji et al.
264
(calculated per recipient body weight). There was no differ-
ence in the total numbers of CD3+ cells between the study
and control marrow grafts. The study group had fewer
CD4+ cells (P = .02) but more CD8+ cells (P = .02), resulting
in a marked decrease in the CD4+:CD8+ ratio (P = .018).
Engraftment
All patients achieved trilineage engraftment. Patients in
the study group had a consistently faster time to engraftment
in both neutrophils and platelets (Table 3). The median
times to ANC > 0.5 × 109/L were 15 days in the study group
versus 21 days in the control group (P = .001). The median
times to platelets > 20 × 109/L were 17.5 days in the study
group versus 24 days in the control group (P = .001). Patients
receiving G-CSF–primed marrow had fewer platelet transfu-
sions before hematopoietic reconstitution (P = .01).
Graft-versus-Host Disease
Eleven (34.4%) of 32 patients in the study group and
8 (44.4%) of 18 patients in the control group developed
grade I acute GVHD, which was not a signiﬁcant difference
(P = .8). Two (6.3%) of 32 patients in the study group and
5 (27.8%) of 18 patients in the control group developed
grades II to IV acute GVHD (P = .032) (Figure 1). The
acute GVHD of the 2 patients in the study group was grade
II, limited only to the skin and controlled by a short course
of methylprednisone. Of the 5 patients with grades II to IV
acute GVHD in the control group, 1 died of acute GVHD
of the gastrointestinal tract and 1 died of acute and chronic
GVHD of the liver. Four (33.3%) of the 12 patients in the
control group who survived more than 6 months had
chronic GVHD. Three patients had limited disease, and
1 patient died of extensive disease. Six (24%) of the
25 patients in the study group who survived more than
6 months developed chronic GVHD either during or after
CsA was tapered. There were no GVHD-related deaths in
the study group. The difference between incidence rates of
chronic GVHD in the study and control groups was not
signiﬁcant (24% versus 33.3%, P = .41).
Follow-up
The median follow-up time was 24 months (range,
6-50 months) in the study group and 26 months (range,
7-48 months) in the control group. Four (12.5%) of
32 patients in the study group and 2 (11.1%) of 18 patients
in the control group died of disease relapse (P = .87). Of the
4 patients in the study group who died of relapse, 3 were in
CML accelerated phase prior to undergoing transplantation.
Three patients in the study group (9.4%) and 4 patients in
the control group (22.2%) died of transplantation-related
causes (Table 4). As of this report, 25 of 32 patients in the
study group and 12 of 18 patients in the control group were
still alive. The estimated probabilities of disease-free sur-
vival at 3 years for the study group and control group were
78.1% and 66.7%, respectively (Figure 2) and were not sta-
tistically signiﬁcant according to the log-rank test (P = .32).
However, there was a trend in favor of improved disease-
free survival in the study group.
DISCUSSION
This study, performed during 1997-2000 in a single
center, compared the outcomes in a homogenous group of
patients with CML of HLA-identical marrow transplantations
with and without donor G-CSF priming prior to the mar-
Table 3. Summary of Engraftment and Transfusion Requirements*
Study Group Control Group P
Days to ANC > 0.5 × 109/L 15 (10-22) 21 (13-29) .001
Days to platelet count > 20 × 109/L 17.5 (12-28) 24 (17-32) .001
Units of red cell transfusion 2 (0-7) 3 (0-10) .3
Units of platelets transfusion 4 (1-9) 7 (4-15) .01
*Values are median (range).
Figure 1. Probability of developing acute grade II to IV GVHD. Figure 2. Disease-free survival rates.
Table 4. Summary of Clinical Outcomes
Study Group Control Group
No. of patients 32 18
Median follow-up (range), mo 24 (6-50) 26 (7-48)
No. of surviving patients 25 12
Causes of death, n
Relapse 4 2
GVHD 0 2
Hepatitis 1 0
Infection 2 2
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row harvest. Many groups have consistently shown that
G-CSF–mobilized PBSCs engraft earlier than non–G-CSF–
stimulated steady-state marrow in matched sibling trans-
plantation settings [3-6]. There were only a few reported
studies comparing G-CSF–primed marrow versus G-CSF–
mobilized PBSCs [12,13] and G-CSF–primed versus non-
primed donor marrow [20,21]. Our results confirmed the
ﬁndings of the Isola and Couban groups [20,21] that G-CSF
donor priming facilitates the marrow engraftment. The
median times for neutrophil engraftment after G-CSF–
primed marrow transplantations were almost identical
among these studies, and there was no difference between
G-CSF–mobilized PBSCs versus G-CSF–primed marrow
transplantations, as summarized in Table 5.
The median times to platelets > 20 × 109/L after G-CSF–
primed marrow transplantation were also signiﬁcantly faster
than those for nonprimed marrow grafts in all 4 studies
(Table 5). G-CSF marrow priming facilitated both neu-
trophil and platelet engraftment, suggesting that G-CSF
increased not only committed myeloid progenitor cells but
also early noncommitted stem cells. The prompt engraft-
ment observed in G-CSF–primed marrow transplantations
was probably caused by the relatively high numbers of
CD34+ cells infused. Mavroudis et al. reported 4 incidents of
late graft failure after the initial engraftment of 12 patients
who received G-CSF–stimulated marrow grafts with CD34+
cell selection [22]. We and other groups saw no incidence of
late graft failure in the patients who received G-CSF–
primed marrow without further manipulation.
The G-CSF doses used for donor-marrow priming dif-
fered in these 4 studies (Table 5). The neutrophil and platelet
engraftment were very similar among the G-CSF–primed
marrow transplantation studies. We used postgrafting G-CSF
treatment until the ANC was > 0.5×109/L, and other study
groups did not use postgrafting G-CSF. It appeared that
postgrafting G-CSF did not further facilitate engraftment if
the donor marrow had already been exposed to G-CSF. The
question that remains to be answered is, what is the optimal
dose of G-CSF for donor-marrow priming?
Bensinger et al. compared G-CSF–mobilized PBSCs to
historical steady-state marrow transplantations and reported a
similar incidence of GVHD, although the T-cell numbers in
G-CSF–mobilized PBPCs were often 10 times higher than
those in the marrow [6]. Serody et al. and Darrant and Mor-
ton compared the incidence rates of acute and chronic
GVHD in patients treated with G-CSF–mobilized PBSCs
and those treated with G-CSF–primed marrow [12,13]. Both
studies found that patients treated with G-CSF– primed mar-
row grafts had lower incidence rates of both acute and
chronic GVHD, especially chronic GVHD. One of the
explanations for the lower rates was that the numbers of
T-cells in the G-CSF–primed marrow were much lower than
the numbers in the G-CSF–mobilized PBSCs. The incidence
of acute GVHD in our study was surprisingly low in the
patients who received G-CSF–primed marrow grafts and
postgrafting G-CSF. Only 2 (6.3%) of 32 patients developed
grade II acute GVHD, which was limited to the skin and
quickly resolved with a short course of steroid treatment. The
incidence rates of grades II to IV acute GVHD were not only
significantly lower in our study group than in our control
group, but also much lower than the incidence rates for
G-CSF–primed marrow transplantations done by other
groups, as shown in Table 5. Serody et al. reported a 27%
incidence rate of grades II to IV acute GVHD after the
matched sibling G-CSF–primed marrow transplantations.
Both our study and the study of Serody et al. were done with
patients who received matched sibling transplants with simi-
lar CsA and MTX as GVHD prophylaxis. The major differ-
ence in the studies was that we routinely used postgrafting
G-CSF to ANC > 0.5 × 109/L, whereas the other groups did
not use the postgrafting G-CSF. We used lenograstim, which
is a glycosylated recombinant human G-CSF (Chugai Phar-
maceutical, Tokyo, Japan). The others most likely used ﬁl-
grastim, a nonglycosylated G-CSF (Amgen, Thousand Oaks,
CA), considering that the studies from other groups were
done within the market territory of Amgen company,
although the authors did not speciﬁcally mention the G-CSF
sources in their report. Our results demonstrated that G-CSF
did not change the total numbers of CD3+ T-cells but altered
subsets of T-cells and significantly lowered the CD4:CD8
ratio. It is known that cytokines produced by CD4+ and CD8+
T-cells can be characterized into 2 patterns, Th1 (interleukin
[IL]-2 and interferon-γ) and Th2 responses (IL-4 and IL-10)
[23]. The Th1-type responses are critical for acute GVHD
[24]. Treatment that induces the Th2 response reduces
GVHD [25]. G-CSF polarizes the T-cell differentiation from
Th1- to Th2-type cells and induces Th2 responses with the
production of IL-4 and IL-10 [26]. Tayebi et al. compared
phenotypic and functional properties of lymphocytes from
bone marrow or PBSC donors after G-CSF treatment in a
Table 5. Comparison of Engraftment and Incidence Rates of Acute GVHD from Various Studies
Median Time Median Time
to ANC > to Platelets > Postgrafting Acute
Study Author Donor G-CSF Treatment Types of Grafts 500/mm3, d 20,000/mm3, d G-CSF GVHD (II-IV)
Serody Filgrastim 10 µg/kg/d × 4 d Marrow (n = 26) 16 16 No 27%
Filgrastim 10 µg/kg/d × 4 d PBSCs (n = 20) 17 13 No 60%
Isola Filgrastim 10 µg/kg/d × 2 d Marrow (n = 17) 17 21 No 19%
None Marrow (n = 112) 24 25 No 19%
Ji Lenograstim 3-4 µg/kg/d × 7 d Marrow (n = 32) 15 17.5 Yes 6.3%
None Marrow (n = 18) 21 24 Yes 27.8%
Couban Filgrastim 10-15 µg/kg/d × 4 d Marrow (n = 29) 18 22 No N/A
None Marrow (n = 20) 22 27 No N/A
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randomized study [27]. These researchers found not only that
the lymphocyte counts in the marrow grafts were 10-fold
lower than the counts in the G-CSF– mobilized PBCS grafts,
but also that the production of Th1 cytokines (IL-2, inter-
feron-γ, tumor necrosis factor) after G-CSF treatment was
also severely impaired [27]. Thus, modulation of cytokine
production by G-CSF may help to explain the surprisingly
low incidence of clinical acute GVHD observed in our study
group with the combination of donor G-CSF marrow prim-
ing and postgrafting G-CSF treatment. Whether the glycosy-
lation of G-CSF increases T-cell polarization and Th2
cytokine production remains to be answered.
The incidence rates of chronic GVHD and relapse are
relatively low in CML patients with HLA-identical sibling
transplantations compared to patients with mismatched trans-
plantations and those with advanced/high-risk leukemia/
lymphoma. Our study showed a trend of decreasing of
chronic GVHD and improving disease-free survival in the
patients who received the G-CSF–primed marrow grafts
(78.1% versus 66.7%), but the difference did not reach sta-
tistical signiﬁcance according to the log-rank test. To com-
pare the survival curves using a 2-tailed log-rank test at the
0.05 level of signiﬁcance with 1 group having 78.1% long-
term survival rate and the other a 66.7% survival rate would
require us to randomize 243 patients per treatment arm
(80% power) or 326 patients per treatment arm (90%
power). Enrolling this number of patients would require an
8- to 10-year enrollment period for a single center and, cer-
tainly, would need a multicenter collaborative study.
In summary, the present study describes the allogeneic
marrow transplantation outcome for 50 patients with CML
using HLA-identical sibling marrow grafts with and without
G-CSF donor priming prior to the marrow harvest. G-CSF
donor priming increased the numbers of CD34+ and
CFU-GM cells and facilitated both neutrophil and platelet
reconstitution. The median times to neutrophil and platelet
engraftment were comparable to those of G-CSF–mobilized
PBSCs. Postgrafting G-CSF treatment did not further accel-
erate the engraftment if the donor marrow had been primed
with G-CSF. However, the postgrafting G-CSF treatment
administered to the recipients appeared to reduce the inci-
dence of acute GVHD. G-CSF alters the CD4:CD8 ratio
and polarizes T-cells from Th1 to Th2 responses. The com-
bination of G-CSF donor-marrow priming and postgrafting
G-CSF treatment dramatically reduced the incidence of
grades II to IV acute GVHD to a surprisingly low rate, 6.3%
in HLA-identical sibling marrow transplantations. There
were no significant differences in the incidence rates of
chronic GVHD, relapse rates, and overall disease-free sur-
vival rates between the G-CSF–primed and nonprimed mar-
row transplantation patients during a median of 24 months
of follow-up. However, there was a trend in favor of
improved disease-free survival at 3 years in G-CSF–primed
marrow transplantation patients. A multicenter collaborative
trial with large patient numbers is warranted.
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